US 11,987,631 B2
Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
Alemseged Truneh, Sudbury, MA (US); Daniel Olive, Marseilles (FR); Christine Pasero, Marseilles (FR); and Aude De Gassart, Marseilles (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); UNIVERSITÉ AIX MARSEILLE, Marseilles (FR); INSTITUT JEAN PAOLI & IRENE CALMETTE, Marseilles (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, Paris (FR)
Appl. No. 17/264,507
Filed by Imcheck Therapeutics SAS, Marseilles (FR); INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); Universite d'Aix Marseille, Marseilles (FR); Institut Jean Paoli & Irene Calmettes, Marseilles (FR); and Centre National de la Recherche Scientifique—CNRS, Paris (FR)
PCT Filed Jul. 31, 2019, PCT No. PCT/EP2019/070693
§ 371(c)(1), (2) Date Jan. 29, 2021,
PCT Pub. No. WO2020/025703, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. 18306050 (EP), filed on Aug. 1, 2018; and application No. 19153992 (EP), filed on Jan. 28, 2019.
Prior Publication US 2022/0112289 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 9/19 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 9/19 (2013.01); A61K 38/2013 (2013.01); A61K 38/2086 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 39/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/56 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of an anti-BTN3A antibody comprising a variable heavy chain polypeptide VH of SEQ ID NO:1 and a variable light chain polypeptide VL of SEQ ID NO:2 or SEQ ID NO: 3.